Question

Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura

Answer 1

Both increased the platelet counts in healthy subjects and in over two thirds of patients with ITP both before and after splenectomy; responses were maintained for at least 1 year. Romiplostim and eltrombopag are now US Food and Drug Administration approved for the second-line treatment of patients with ITP.
I hope may I help you+×:+;{××÷+×